OBGYN.net Staff

Articles by OBGYN.net Staff

With a number of clinical studies now completed, the launch of drospirenone/ethinyl estradiol (Yasmin®) in the United States and Europe is expected in the near future. An international panel of physicians involved with the development of drospirenone/ethinyl estradiol recently described the potential benefits of the new oral contraceptive (OC) to clinicians attending an industry-sponsored symposium held during the XVI FIGO World Congress of Gynecology and Obstetrics.

There has been an explosion of hormone replacement therapy research over the past few years. The task of wading through the data to determine what is best for a particular patient, however, can be daunting at best and confusing at worst, said Dr. Karen Carlson, Massachusetts General Hospital, Boston, to delegates at the Pri-Med East in Boston.

A report just published in the Journal of the American Medical Association confirmed previous studies which found that women who take hormone replacement therapy (HRT) may develop denser breast tissue, which in turn may make it more difficult to detect breast cancer through mammography.

This is adapted from an interview with Dr. Howard Glazer, who has developed a treatment for this condition using a form of biofeedback. This initial interview, covers the history of the disease, as well as Dr. Glazer's background.

In an extensive, multi-center clinical treatment trial, Canadian researchers evaluated the outcomes of 538 cases of uterine artery embolization for fibroids. Between 20% and 50% of women develop uterine fibroids, benign tumors in the muscular tissue of the uterus that can seriously impact their health and well-being.

A recent survey of ob/gyns (N = 308) reported that respondents who indicated they had prior training in office uterine evacuation and/or induced abortion also reported using office uterine evacuation more frequently as compared to those providers without any training. The operation room was used more often by those respondents who did not have any induced abortion training.

On December 6, 1999, under Public Law 106-129, the Agency for Health Care Policy and Research (AHCPR) was reauthorized and renamed the Agency for Healthcare Research and Quality (AHRQ).

Although testosterone is generally considered to be a male hormone, it is produced in small amounts by the ovary. Other hormones with testosterone-like effects are also produced by both the ovary and the adrenal gland.

Incompetent cervix is a condition where recurrent mid-trimester pregnancy loss complicates a pregnancy. Incompetent cervix is diagnosed in I in 2000 pregnancies, and has been determined as the cause of approximately 15% of all recurrent pregnancy loss.